No Data
Individual Investors Own 39% of BGI Genomics Co., Ltd. (SZSE:300676) Shares but Private Companies Control 49% of the Company
Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market Analysis and Forecast Report 2024, With Focus on BGI Genomics and Annoroad Gene Technology
A model of the integration of precision medical and technology, bgi genomics (300676.SZ) received the "Annual Excellence Award for Health Enterprises."
Health is not only the cornerstone of personal quality of life but also an important factor for social stability and economic development. Nowadays, with the improvement of living standards and increased health awareness, people's attention to health issues has reached unprecedented heights. In the face of this global trend, many enterprises have invested in the big health industry, committed to improving the quality and efficiency of medical services through technological innovation to meet the growing health demands. In this context, bgi genomics (300676.SZ) has excelled in the deep integration of technological innovation and precision medical, at the recent "9th Glorious Gathering Global".
Japan Non-Invasive Prenatal Testing Market Size, Trends, Growth and Forecasts 2024-2032 With Competitive Analysis of SR, BGI Genomics, Macrogen Japan, and LSI Medience - ResearchAndMarkets.com
Health Check: How Prudently Does BGI Genomics (SZSE:300676) Use Debt?
Asia-Pacific Metagenomics Market Research 2024-2033 With Competitive Analysis of Leading Players - BGI Genomics, MGI Tech, and Macrogen - ResearchAndMarkets.com
Are BGI Genomics Co., Ltd.'s (SZSE:300676) Mixed Financials Driving The Negative Sentiment?
